BYM338 (Bimagrumab)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BYM338 (Bimagrumab), covering 2018-03-13 to 2018-03-13. Get the full timeline:
Most recent: Clinical Trial Update: An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 [Phase 3]